241 related articles for article (PubMed ID: 28324595)
1. Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus.
Shook BC; Lin K
Top Curr Chem (Cham); 2017 Apr; 375(2):40. PubMed ID: 28324595
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus: prospects for new and emerging therapeutics.
Jorquera PA; Tripp RA
Expert Rev Respir Med; 2017 Aug; 11(8):609-615. PubMed ID: 28574729
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
Empey KM; Peebles RS; Kolls JK
Clin Infect Dis; 2010 May; 50(9):1258-67. PubMed ID: 20235830
[TBL] [Abstract][Full Text] [Related]
4. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O
Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus infections: recent prospects for control.
Sidwell RW; Barnard DL
Antiviral Res; 2006 Sep; 71(2-3):379-90. PubMed ID: 16806515
[TBL] [Abstract][Full Text] [Related]
6. [Prospects For the Use of Peptides against Respiratory Syncytial Virus].
Shilovskiy IP; Andreev SM; Kozhikhova KV; Nikolskii AA; Khaitov MR
Mol Biol (Mosk); 2019; 53(4):541-560. PubMed ID: 31397431
[TBL] [Abstract][Full Text] [Related]
7. New therapies for acute RSV infections: where are we?
Xing Y; Proesmans M
Eur J Pediatr; 2019 Feb; 178(2):131-138. PubMed ID: 30610420
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future.
Weisman LE
Cardiovasc Hematol Agents Med Chem; 2009 Jul; 7(3):223-33. PubMed ID: 19689261
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus entry inhibitors targeting the F protein.
Sun Z; Pan Y; Jiang S; Lu L
Viruses; 2013 Jan; 5(1):211-25. PubMed ID: 23325327
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies.
Shang Z; Tan S; Ma D
Int J Biol Sci; 2021; 17(14):4073-4091. PubMed ID: 34671221
[TBL] [Abstract][Full Text] [Related]
11. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
[TBL] [Abstract][Full Text] [Related]
12. State of the Art in Respiratory Syncytial Virus Drug Discovery and Development.
Cockerill GS; Good JAD; Mathews N
J Med Chem; 2019 Apr; 62(7):3206-3227. PubMed ID: 30411898
[TBL] [Abstract][Full Text] [Related]
13. New options in the treatment of respiratory syncytial virus disease.
Mejias A; Ramilo O
J Infect; 2015 Jun; 71 Suppl 1():S80-7. PubMed ID: 25922289
[TBL] [Abstract][Full Text] [Related]
14. Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus.
Sun BW; Zhang PP; Wang ZH; Yao X; He ML; Bai RT; Che H; Lin J; Xie T; Hui Z; Ye XY; Wang LW
Molecules; 2024 Jan; 29(3):. PubMed ID: 38338343
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of respiratory syncytial virus infections: the final breakthrough.
De Clercq E
Int J Antimicrob Agents; 2015 Mar; 45(3):234-7. PubMed ID: 25684638
[TBL] [Abstract][Full Text] [Related]
16. Novel therapies for an old virus: treatment of RSV infections in the 21st Century.
Lüsebrink J; Schildgen V; Schildgen O
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1125-9. PubMed ID: 19883332
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
[TBL] [Abstract][Full Text] [Related]
18. New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase.
Fearns R; Deval J
Antiviral Res; 2016 Oct; 134():63-76. PubMed ID: 27575793
[TBL] [Abstract][Full Text] [Related]
19. Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
Blockus S; Sake SM; Wetzke M; Grethe C; Graalmann T; Pils M; Le Goffic R; Galloux M; Prochnow H; Rox K; Hüttel S; Rupcic Z; Wiegmann B; Dijkman R; Rameix-Welti MA; Eléouët JF; Duprex WP; Thiel V; Hansen G; Brönstrup M; Haid S; Pietschmann T
Antiviral Res; 2020 May; 177():104774. PubMed ID: 32197980
[TBL] [Abstract][Full Text] [Related]
20. In search of a small-molecule inhibitor for respiratory syncytial virus.
Douglas JL
Expert Rev Anti Infect Ther; 2004 Aug; 2(4):625-39. PubMed ID: 15482225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
